Obesity and Cardiovascular Disease: The Emerging Role of Inflammation
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Obesity is a growing public health challenge across the globe. It is associated with increased morbidity and mortality. Cardiovascular disease (CVD) is the leading cause of mortality for people with obesity. Current strategies to reduce CVD are largely focused on addressing traditional risk factors such as dyslipidemia, type 2 diabetes (T2D) and hypertension. Although this approach is proven to reduce CVD, substantial residual risk remains for people with obesity. This necessitates a better understanding of the etiology of CVD in people with obesity and alternate therapeutic approaches. Reducing inflammation may be one such strategy. A wealth of animal and human data indicates that obesity is associated with adipose tissue and systemic inflammation. Inflammation is a known contributor to CVD in humans and can be successfully targeted to reduce CVD. Here we will review the etiology and pathogenesis of inflammation in obesity associated metabolic disease as well as CVD. We will review to what extent these associations are causal based on human genetic studies and pharmacological studies. The available data suggests that anti-inflammatory treatments can be used to reduce CVD, but off-target effects such as increased infection have precluded its broad therapeutic application to date. The role of anti-inflammatory therapies in improving glycaemia and metabolic parameters is less established. A number of clinical trials are currently ongoing which are evaluating anti-inflammatory agents to lower CVD. These studies will further clarify whether anti-inflammatory agents can safely reduce CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MR-Base platform supports systematic causal inference across the human phenome
Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., et al. (2018) · eLife · doi:10.7554/elife.34408 · Cited by 7,959
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 2×
“CHIP may also be increased in patients with T2D (66).”
BackgroundFinucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050 · cited 1×
“Obesity is a chronic disease which increases mortality and morbidity and has reached epidemic proportions (1, 2).”
BackgroundEfficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159 · cited 4×
“It concluded that low-dose colchicine resulted in a significantly lower risk of cardiovascular events compared to placebo post-myocardial infarction (79).”
BackgroundMethodInfluentialMechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Yusuf, S., Hawken, S., Ôunpuu, S., Bautista, L., Franzosi, M. G., Commerford, P., Lang, C. C., Rumboldt, Z., Onen, C. L., Lisheng, L., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67663-5 · Cited by 2,903
The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873 · cited 16×
“Superficial erosion of the plaque due to loss of the endothelial monolayer can result in entrapped neutrophils releasing “neutrophil extracellular traps,” which further propagate inflammation and thrombus formation with healing leading to stenosis of the vessel (8, 9).”
BackgroundInfluential
Cited by
Hallmarks of cardiovascular ageing
Abdellatif, M., Rainer, P. P., Sedej, S., & Kroemer, G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00881-3 · Cited by 274
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Adiposity, fat-free mass and incident heart failure in 500 000 individuals
Oguntade, A. S., Taylor, H., Lacey, B., & Lewington, S. (2024) · Open Heart · doi:10.1136/openhrt-2024-002711 · Cited by 31
“103 Many of these studies have far fewer events than the UKB and the reported estimates are, therefore, more imprecise than UKB.”
ResultWang, Q., Peng, J., Tian, Y., Li, J., Cai, J., & Qin, W. (2025) · Current Microbiology · doi:10.1007/s00284-024-03974-5 · Cited by 5
“Obesity plays a critical role in the pathogenesis of CVDs [10].”
Metadata
- Authors
- Khafagy, R., & Dash, S.
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2021-10-25
- Volume
- 8
- Pages
- 768119-768119
- ISSN
- 2297-055X (ISSN-L)
- OpenAlex
- W3209300046
- Cited by
- 60
- References
- 44
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. https://app.cochat.ai/papers/10.3389/fcvm.2021.768119
- The paper
- Khafagy, R., & Dash, S. (2021). Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2021.768119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.